XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.05

-3.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (16477)	11/22/2003 11:14:05 AM
From: Robert K.	Read Replies (1) of 17367

The role of CD8+ cells and CD11a in the rejection-reaction of the allogeneic microskin grafting. Lin SD, Chai CY, Tsai CC, Chou CK, Lin TM. Department of Surgery, Kaohsiung Medical College Hospital, Taiwan, Republic of China. By using histological tissue sections and immunohistochemical stains, the rejection-reaction of the allogeneic microskin grafting of rabbit-skin wounds was studied. The results revealed that the rejection started early in the days following transplantation. In the second week following transplantation, severe graft rejection with epithelial destruction was noted. In addition, an increase of CD8+ cells and expression of the adhesion molecule-CD11a-were also noticed and persisted throughout the days following transplantation. These findings suggest that the CD8+ cells and CD11a may play a major role in the rejection of allogeneic skin grafting.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next